232 related articles for article (PubMed ID: 25638724)
1. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Maeda M; Murakami Y; Watari K; Kuwano M; Izumi H; Ono M
Lung Cancer; 2015 Mar; 87(3):265-71. PubMed ID: 25638724
[TBL] [Abstract][Full Text] [Related]
2. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
[TBL] [Abstract][Full Text] [Related]
3. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
4. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Noro R; Gemma A; Miyanaga A; Kosaihira S; Minegishi Y; Nara M; Kokubo Y; Seike M; Kataoka K; Matsuda K; Okano T; Yoshimura A; Kudoh S
Int J Oncol; 2007 Nov; 31(5):1157-63. PubMed ID: 17912443
[TBL] [Abstract][Full Text] [Related]
5. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Yang B; Yang ZG; Gao B; Shao GG; Li GH
Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
[TBL] [Abstract][Full Text] [Related]
9. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
[TBL] [Abstract][Full Text] [Related]
10. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Kokubo Y; Gemma A; Noro R; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Shibuya M; Kudoh S
Br J Cancer; 2005 May; 92(9):1711-9. PubMed ID: 15870831
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Yamasaki F; Johansen MJ; Zhang D; Krishnamurthy S; Felix E; Bartholomeusz C; Aguilar RJ; Kurisu K; Mills GB; Hortobagyi GN; Ueno NT
Cancer Res; 2007 Jun; 67(12):5779-88. PubMed ID: 17575145
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Wang Q; Li M; Hu C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882
[TBL] [Abstract][Full Text] [Related]
13. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
14. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
15. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
16. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
17. Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.
Terai H; Soejima K; Yasuda H; Sato T; Naoki K; Ikemura S; Arai D; Ohgino K; Ishioka K; Hamamoto J; Kanai Y; Betsuyaku T
Int J Oncol; 2015 Jan; 46(1):430-6. PubMed ID: 25353970
[TBL] [Abstract][Full Text] [Related]
18. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
19. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Tabara K; Kanda R; Sonoda K; Kubo T; Murakami Y; Kawahara A; Azuma K; Abe H; Kage M; Yoshinaga A; Tahira T; Hayashi K; Arao T; Nishio K; Rosell R; Kuwano M; Ono M
PLoS One; 2012; 7(7):e41017. PubMed ID: 22815900
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
